Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study
- PMID: 33263170
- PMCID: PMC8357646
- DOI: 10.1007/s00277-020-04361-3
Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study
Abstract
Iron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient's perceived quality of life. A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations. In this multicentric randomized study, we analyze the cost-effectiveness of intravenous sodium ferrigluconate vs oral Sucrosomial iron in patients with iron deficiency anemia refractory/intolerant to oral iron sulfate without other interfering factors on iron absorption.
Keywords: High doses; Intravenous sodium ferrigluconate; Iron deficiency anemia; Oral Sucrosomial iron; Refractoriness/intolerance to oral iron sulfate.
© 2020. The Author(s).
Conflict of interest statement
MN acted as the consultant for Bayer, BIOFVIIIx, Novonordisk, and Amgen, and received speaker fees from Kedrion, Octapharma, Baxalta, CSLBehring, Novonordisk, Bayer, and Sobi. All other authors have no relevant conflicts of interest to declare.
Figures
References
-
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
-
- Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, Flaxman SR, Pullan RL, Brooker SJ, Murray CJL. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–624. doi: 10.1182/blood-2013-06-508325. - DOI - PMC - PubMed
-
- WHO (2001) Iron deficiency anemia assessment, prevention, and control: a guide for programme managers. Geneva: World Health Organization WHO/NHD/01.3
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
